Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No R/S will be needed!
Yes Dec. 2014
More press releases» Press Release
Market Report, "Amarantus Bioscience Holdings, Inc. (AMBS) - Product Pipeline Analysis, 2014 Update", Published
Recently published research from GlobalData, "Amarantus Bioscience Holdings, Inc. (AMBS) - Product Pipeline Analysis, 2014 Update", is now available at Fast Market Research
Boston, MA -- (SBWIRE) -- 06/11/2014 -- Amarantus BioScience has acquired rights to two diagnostic platforms for the diagnosis of neurodegenerative diseases and oncology such as nuropro diagnostic blood test platform and lympro Alzheimer's disease diagnostic blood test. The company offers treatment services for neurodegenerative diseases such as Parkinson's disease, ALS and alzheimer's disease, and cardiovascular diseases including myocardial infarction, coronary artery disease and heart failure. The company holds license to Eltoprazine, owns intellectual property rights for Mesencephalic-Astrocyte-derived Neurotrophic Factor and license to the LymPro Test. Its partners include Banyan Biomarkers, Brewer Sports International, Memory Dx, LLC, and Psychogenics, Inc. Amarantus BioSciences is headquartered in Sunnyvale, the US.
View Full Report Details and Table of Contents
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Amarantus Bioscience Holdings, Inc.
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Companies Mentioned in this Report: Amarantus Bioscience Holdings, Inc. (AMBS)
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Medical Devices research reports at Fast Market Research
You may also be interested in these related reports:
-
Just wait for Lympro revenue guidance and a JnJ partnership for PD!!!! IMO
Me either!
Once we get revenue guidance and up list to a major exchange where the big fund guys by millions of shares, this will provide more transparency than any ad campaign! Things are getting exciting, JnJ.......
And when they start using it for TBI, holy cow!
I don't think Gerald would sell the company for less than $400M currently.
John won't allow it....
I was thinking the same thing......
p.s. Is anyone going to try to meet with Gerald next week in Los Angeles?
That's Dave's job!
I'll go along with that...
It seemed to me that Gerald was somewhat going through the motions of making the presentation today. It was as though what he was stating was somewhat irrelevant to the "big picture" or what is already "in the works".
Reminded me of myself on the last hour of the last day of a three day trade show when I've already locked up three major new accounts and all I want to do is go home but I still have to make the same sales pitch to the last visitor to the booth.
I think even Gerald is getting a bit impatient with getting things moving.
2b/3 interesting......
Great article!
yes very nice! JJ are you the alter ego of BH? LoL
Tic,toc,tic,toc.......
ROW is the correct term.
If that were true it would have killed him!
Maybe, just maybe he chuckled because he is giddy at the amount of shares he owns and he knows what's going on..... Just as reasonable.
I know but unlike you I own a good amount at those levels, I wouldn't hold your breath for those shares.....
Use of unorthodox 'massage parlor' techniques which, while following provisions of GAAP, paint a desired (negative or positive, as the case may be) picture of a firm's finances. For example, selling an asset (whose market value is high but book value is low) to create non-operating profit that offsets operating loss. Unlike cooking the books, creative accounting is generally legal. Euphemistically also called financial engineering or earnings management. See also creative financing.
Read more: http://www.businessdictionary.com/definition/creative-accounting.html#ixzz30KuycWiX
Like Kaiser?
Why creep a board when you own no shares.
Lympro...DR. Lowe said concusion's when GC was talking about revenue, this test will be in every sports teams locker room as well as every school in the country!!! Wow, hang on folks!
Me too, I'll give you 70k right now!
DR posting like crazy after being quite for some time now? Big news must be coming tomorrow.......
Soo many catalysts due 2H14 what's your pick for the first one met/announced? I chose Retrospective / prognostic 9 year patient record clinical study (1H-14).....!
Umm, for transparency????
Maybe not but it doesn't matter to me, we need to get the PPS over 5.00 not because of the OTC but to allow the big boys to start accumulating! That's the meat and potatoes....
Back to green days, 10k is done and the dilution is no worse then we thought it was! The foundation is almost complete, exciting days ahead.... GLTA
Weigh the good and the bad, that should cheer you up!
Happy Easter.
Remember when the majority of people are down on a stock and sell, that's a firm signal to buy! Investing 101... God bless all this Easter!
Better question, why are you still here?
Warp, thank you for your thoughts and comments! Nice to see another calm gun slinger on here.
I see the hens are still whining today... Everyone is dumping their shares but the price didn't drop much?? We have all bought into AMBS because of the science do you think LP would bail for something this simple.... Let me help you out no they have a bit more inside information than most and they're not going anywhere... I'm sure GC advised them and I'm also sure they would send a body if need be to protect their investment! If you believe in your due diligence then relax and let this company run it's course.
They need to hire a shrink to deal with all these panic struck investors!
This MB is pure entertainment, you hens wouldn't know what to do if you couldn't create drama!!!
I'm in for a million shares, 05:15 PST